Internship

Summer Intern

Quality Assurance

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$22Hourly

Pasadena, CA, USA

Category
QA & Testing
Quality Assurance

You match the following Arrowhead Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Currently enrolled student at an Accredited University or College and majoring in Life Sciences, Quality Assurance, Regulatory Affairs, or a related field
  • Basic understanding of pharmaceutical quality systems (QMS) and regulatory compliance.
  • Excellent verbal and written communication skills
  • Ability to work independently while collaborating with Quality, Contracts, and Regulatory teams
  • Strong problem-solving skills
  • Eagerness to learn
Responsibilities
  • Assist in updating and maintaining vendor records in the Quality Management System (QMS) to improve system integration and data accuracy.
  • Upload and organize vendor licenses, certificates, and agreements, ensuring proper tracking and accessibility.
  • Support document management and compliance efforts, including linking records across systems for streamlined access.
  • Assist in data consistency and quality control, ensuring accurate and up-to-date information across multiple platforms.
  • Help prepare documentation for regulatory submissions and inspections, organizing and reviewing required materials.
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines that treat severe diseases by targeting and silencing specific genes using RNA interference (RNAi). This method reduces gene expression, allowing for significant and lasting effects on conditions like cystic fibrosis and hepatitis B. The company stands out by focusing exclusively on RNAi-based therapies, addressing unmet medical needs in the biotechnology market. Their goal is to provide new treatment options for diseases with limited or no effective therapies.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$4.7M

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead secured a $500 million facility with Sixth Street for pipeline advancement.
  • Positive Phase 2 data for plozasiran shows promise in treating severe hypertriglyceridemia.
  • Collaboration with Sarepta Therapeutics brings significant financial and research benefits.

What critics are saying

  • Increased competition from companies like Alnylam Pharmaceuticals in the RNAi space.
  • Potential regulatory scrutiny could delay clinical trials for RNAi therapies.
  • Financial instability risk due to reliance on strategic financing agreements.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its research and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.

Endpoints News
Aug 14th, 2024
Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells

Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be "gentler" than currently available GLP-1 products...

Business Wire
Aug 9th, 2024
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has entered into a strategic financing agreement with Sixth Street for signific

Defense World
May 12th, 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR) receives "buy" Rating from Chardan Capital.